Rosuvastatin (crestor)?

Rosuvastatin (brand name Crestor)
A statin (HMG‑CoA reductase inhibitor) used to lower LDL‑cholesterol and reduce cardiovascular risk.

---

1. What it’s for

Indication	Typical goal
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)	↓ LDL‑C ≥ 30 % (or ≥ 50 % if very high risk)
Secondary prevention (after MI, stroke, PAD)	Same LDL‑C targets
Homozygous familial hypercholesterolemia (HFH)	Often combined with other lipid‑lowering agents
Mixed dyslipidemia	Reduce LDL‑C, triglycerides (moderately) and raise HDL‑C

---

2. How it works

• Inhibits HMG‑CoA reductase, the rate‑limiting enzyme in cholesterol synthesis → ↓ hepatic cholesterol → ↑ LDL‑R → ↑ clearance of LDL from blood.

---

3. Dosage & administration

Population	Starting dose	Titration	Max dose
Adults	5 mg once daily (morning or evening)	Increase by 5 mg increments every 4 weeks	40 mg daily
HFH or very high‑risk	10 mg daily	Increase by 5 mg every 4 weeks	20 mg daily
Elderly / CKD stage 4+	5 mg daily	Caution: use 2.5 mg if creatinine clearance < 30 mL/min	10 mg daily
Pediatric (≥10 yrs)	5–10 mg daily	↑ 5 mg every 4 weeks	10 mg daily

• Take with food? Statins are best taken with a meal to reduce GI upset.
• Avoid grapefruit or grapefruit‑juice products (they can increase rosuvastatin levels).
• Split doses (e.g., 10 mg in the evening + 5 mg in the morning) are rarely necessary; a single daily dose is usually enough.

---

4. Common side effects

Category	Frequency	Notes
Musculoskeletal (myalgia, myositis, rhabdomyolysis)	<1 % (most mild)	Higher risk with high doses, renal impairment, or concurrent statin.
Hepatic (↑ ALT/AST)	1–2 %	Check LFTs before starting and 4–6 weeks after dose change.
GI (nausea, diarrhea, constipation)	5–10 %	Usually transient.
Cognitive (memory loss, confusion)	<1 %	Rare; reversible when stopped.
Injection‑site reactions (if given IV; rare)	<0.5 %	Mostly in clinical settings.

---

5. Serious adverse events

• Rhabdomyolysis: Severe muscle pain, dark urine, ↑CK.
• Liver injury: ↑ALT/AST >3× ULN with symptoms or >5× ULN asymptomatic → discontinue.
• New‑onset diabetes: Small ↑ risk; monitor fasting glucose if high baseline risk.
• Allergic reactions: Rash, anaphylaxis extremely rare.

---

6. Drug interactions (high‑risk)

Drug	Interaction	How to manage
Simvastatin, atorvastatin	↑CYP3A4 inhibition → ↑ rosuvastatin	Avoid co‑administration
Ketoconazole, itraconazole	↑CYP3A4 inhibition	Avoid or reduce dose
Cyclosporine, voriconazole	↑CYP3A4 inhibition	Avoid or reduce dose
Ritonavir, cobicistat	↑CYP3A4 inhibition	Avoid or reduce dose
Gemfibrozil	↑myopathy risk	Avoid combination
Nifedipine (long‑acting)	↑CYP3A4 inhibition	Avoid or reduce dose
Amiodarone	↑CYP3A4 inhibition	Avoid or reduce dose
Proton‑pump inhibitors	↓ rosuvastatin absorption	Consider timing (take >2 h after)
Warfarin	↑INR (rare)	Monitor INR closely
Antifungals, antivirals	↑CYP3A4 inhibition	Reduce dose or avoid

Always check for newer data or additional interactions in the prescribing information or an up‑to‑date drug database.

---

7. Contraindications

• Active liver disease (elevated AST/ALT >3× ULN)
• Unexplained myopathy or CK >5× ULN
• Pregnancy (category X) and lactation (avoid)
• Known hypersensitivity to rosuvastatin or any component

---

8. Special populations

Group	Key points
Renal impairment	CKD Stage 3–4: use 2.5 mg or 5 mg; stage 5: not recommended (dose not established).
Hepatic impairment	Mild: normal dose; moderate: 5 mg; severe: avoid.
Pediatrics	Approved 10 mg daily in children ≥10 yrs for familial hypercholesterolemia.
Elderly	May tolerate lower doses; watch for myopathy and CKD.
Pregnancy	Not recommended.
Breastfeeding	Data limited; generally avoided.

---

9. Monitoring recommendations

Parameter	Timing	Rationale
LFTs	Before starting, 4–6 weeks after dose change, then periodically (e.g., 3–12 months)	Detect hepatotoxicity
CK	Baseline; if myalgias or unexplained muscle pain	Detect rhabdomyolysis
Lipids (LDL‑C, HDL‑C, TG)	4–12 weeks after initiating/titrating	Assess efficacy
Fasting glucose/HbA1c	In patients with risk of diabetes	Monitor metabolic effect
Drug levels	Rarely needed unless high suspicion of interaction	Not routine

---

10. Lifestyle adjuncts

• Diet: Reduce saturated fats, trans‑fats, cholesterol; increase soluble fiber (oats, barley).
• Exercise: ≥150 min moderate aerobic activity/week.
• Weight management: Target BMI 18.5–24.9 kg/m².
• Alcohol: Limit to ≤2 drinks/day for men, ≤1 drink/day for women.
• Smoking cessation: Essential for ASCVD risk reduction.

---

11. Patient counseling tips

• Take consistently at the same time each day – daily dosing is key.
• Report muscle pain, weakness, or dark urine immediately.
• Avoid grapefruit and grapefruit juice – can raise levels.
• Check for other medications – ask about supplements, herbal products.
• Keep appointments for lab monitoring – helps catch liver or muscle issues early.
• Maintain healthy lifestyle – medication works best with diet & exercise.

---

12. Quick reference (dose table)

Condition	Goal	Dose (max)
ASCVD, FH, FH	↓LDL‑C ≥ 30 % (or ≥ 50 % high risk)	5–40 mg daily
Homozygous FH	↑LDL‑C > 100 mg/dL	10 mg daily (often combined with PCSK9 inhibitors)
CKD (CrCl 30–59 mL/min)	Safe	5 mg daily (avoid >10 mg)
Severe renal disease (CrCl <30 mL/min)	Not recommended	—

---

Bottom line

Rosuvastatin (Crestor) is a potent, once‑daily statin that effectively lowers LDL‑cholesterol and reduces cardiovascular events when used appropriately. The key is starting at a low dose, titrating carefully, monitoring liver and muscle enzymes, avoiding high‑risk drug interactions, and pairing therapy with lifestyle changes. If you’re unsure about any of these aspects, discuss with your prescriber or pharmacist.